Author: Melvina Ford
Publisher: DIANE Publishing
ISBN: 1428933557
Category : Insurance, Pharmaceutical services
Languages : en
Pages : 41
Book Description
Medicaid
Author: Melvina Ford
Publisher: DIANE Publishing
ISBN: 1428933557
Category : Insurance, Pharmaceutical services
Languages : en
Pages : 41
Book Description
Publisher: DIANE Publishing
ISBN: 1428933557
Category : Insurance, Pharmaceutical services
Languages : en
Pages : 41
Book Description
Coverage of Outpatient Prescription Drugs Under Medicare Part B
Author: United States. Congress. House. Committee on Ways and Means. Subcommittee on Health
Publisher:
ISBN:
Category : Medicare
Languages : en
Pages : 208
Book Description
Publisher:
ISBN:
Category : Medicare
Languages : en
Pages : 208
Book Description
Medicaid Outpatient Prescription Drugs: Estimated 2007 Federal Upper Limits for Reimbursement Compared with Retail Pharmacy Acquisition Costs
Author:
Publisher: DIANE Publishing
ISBN: 9781422313725
Category :
Languages : en
Pages : 32
Book Description
Publisher: DIANE Publishing
ISBN: 9781422313725
Category :
Languages : en
Pages : 32
Book Description
Medicaid Outpatient Prescription Drugs
Author: John E. Dicken
Publisher: DIANE Publishing
ISBN: 1437927599
Category : Health & Fitness
Languages : en
Pages : 35
Book Description
Medicaid spent $15 billion on outpatient prescription drugs (PD) in FY 2007. Instead of directly purchasing PD, state Medicaid programs reimburse pharmacies for dispensing them to Medicaid beneficiaries. For certain PD, state Medicaid programs may only receive fed. matching funds for reimburse. up to a max. amount known as a fed. upper limit (FUL). The Deficit Reduction Act of 2005 changed the methodology for calculating FULs. This report found that if AMP-based FULs had been in place in the 2nd qtr. of 2008, they would have been lower than avg. retail pharmacy costs for most of the drugs in the sample and in the nat. aggregate. However, 64 drugs had at least one therapeutically equivalent version with acquisition costs below the FUL. Illus.
Publisher: DIANE Publishing
ISBN: 1437927599
Category : Health & Fitness
Languages : en
Pages : 35
Book Description
Medicaid spent $15 billion on outpatient prescription drugs (PD) in FY 2007. Instead of directly purchasing PD, state Medicaid programs reimburse pharmacies for dispensing them to Medicaid beneficiaries. For certain PD, state Medicaid programs may only receive fed. matching funds for reimburse. up to a max. amount known as a fed. upper limit (FUL). The Deficit Reduction Act of 2005 changed the methodology for calculating FULs. This report found that if AMP-based FULs had been in place in the 2nd qtr. of 2008, they would have been lower than avg. retail pharmacy costs for most of the drugs in the sample and in the nat. aggregate. However, 64 drugs had at least one therapeutically equivalent version with acquisition costs below the FUL. Illus.
Medicaid
Author: United States. General Accounting Office
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 24
Book Description
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 24
Book Description
Medicaid Prescription Drugs
Author: Sandra Olivia Barton
Publisher:
ISBN: 9781634825221
Category : Law
Languages : en
Pages : 114
Book Description
Publisher:
ISBN: 9781634825221
Category : Law
Languages : en
Pages : 114
Book Description
Medicaid Eligibility Quality Control
Author: United States. Social and Rehabilitation Service
Publisher:
ISBN:
Category : Medicaid
Languages : en
Pages : 462
Book Description
Publisher:
ISBN:
Category : Medicaid
Languages : en
Pages : 462
Book Description
How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry
Author:
Publisher: U.S. Government Printing Office
ISBN:
Category : Business & Economics
Languages : en
Pages : 94
Book Description
Publisher: U.S. Government Printing Office
ISBN:
Category : Business & Economics
Languages : en
Pages : 94
Book Description
Making Medicines Affordable
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309468086
Category : Medical
Languages : en
Pages : 235
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Publisher: National Academies Press
ISBN: 0309468086
Category : Medical
Languages : en
Pages : 235
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Rare Diseases and Orphan Products
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309158060
Category : Medical
Languages : en
Pages : 442
Book Description
Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
Publisher: National Academies Press
ISBN: 0309158060
Category : Medical
Languages : en
Pages : 442
Book Description
Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.